http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#Head
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#assertion
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#provenance
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#pubinfo
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#assertion
http://purl.obolibrary.org/obo/DOID_9008
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_9008
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB08904
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#association
http://www.w3.org/2000/01/rdf-schema#label
cimzia is a tumor necrosis factor tnf blocker indicated for reducing signs and symptoms of crohn s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 1 treatment of adults with moderately to severely active rheumatoid arthritis 1 2 treatment of adult patients with active psoriatic arthritis 1 3 treatment of adults with active ankylosing spondylitis 1 4 treatment of adults with active non radiographic axial spondyloarthritis with objective signs of inflammation 1 5 treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy 1 6 cimzia is indicated for reducing signs and symptoms of crohn s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy cimzia is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis ra cimzia is indicated for the treatment of adult patients with active psoriatic arthritis psa cimzia is indicated for the treatment of adults with active ankylosing spondylitis as see clinical studies 14 4 cimzia is indicated for the treatment of adults with active non radiographic axial spondyloarthritis nr axspa with objective signs of inflammation see clinical studies 14 5 cimzia is indicated for the treatment of adults with moderate to severe plaque psoriasis pso who are candidates for systemic therapy or phototherapy see clinical studies 14 6
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB08904
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#provenance
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#pubinfo
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#sig
http://purl.org/nanopub/x/hasSignature
GC+91AzJ8SJ5+sCTPR+T6QLTbR6j85iTrs/08+2UJAp0DMIPcsXym3ZSq2uoxp+G9DJhwjHbQps8gRv/sAWsfhTS/x1NsDgfsIHPUjE1F1LhvF/pLK3NffUOQJ89qD18c4n7hKN0bWBsi0s5mTB4XrkX3Fgs+ZZQSQ6NM1kc9WI=
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs
http://purl.org/dc/terms/created
2021-07-03T15:10:32.435+02:00
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAuQeA9PNxNJ1Dve2kQ4-0UIyErgQ_VQo5iLgj8aXeNNs
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs